A preliminary study on mice revealed that Tfr2 silencing, through small interfering RNAs (Tfr2-siRNA) in a single dose, led to a significant Hepc downmodulation, and increased transferrin saturation within 24 h post-administration, persisting for more than two weeks, and to a recovery from anemia in animal models of ACD [112]. The gene discussed is TF; the disease is anemia (phenotype).